Etalocib
Etalocib
Etalocib (pronunciation: eh-ta-lo-sib) is a medical term referring to a specific type of drug that was developed for the treatment of various types of cancer.
Etymology
The term "Etalocib" is derived from the pharmaceutical nomenclature, where the suffix "-ib" is commonly used for small molecule inhibitors. The prefix "Etalo-" does not have a specific meaning and is used to create a unique name for the drug.
Definition
Etalocib is a small molecule inhibitor that was designed to target and inhibit the Epidermal Growth Factor Receptor (EGFR), a protein that is often overexpressed in many types of cancer. By inhibiting the EGFR, etalocib can potentially slow down or stop the growth of cancer cells.
Usage
Etalocib was primarily investigated for use in the treatment of colorectal cancer, non-small cell lung cancer, and breast cancer. However, clinical trials have shown limited effectiveness, and the development of the drug was discontinued.
Related Terms
- Small molecule inhibitor: A type of drug that can enter cells and interfere with the function of specific proteins.
- Epidermal Growth Factor Receptor (EGFR): A protein found on the surface of some cells to which epidermal growth factor binds, causing the cells to divide.
- Colorectal cancer: A cancer that starts in the colon or the rectum.
- Non-small cell lung cancer: The most common type of lung cancer.
- Breast cancer: A cancer that forms in the cells of the breasts.
External links
- Medical encyclopedia article on Etalocib
- Wikipedia's article - Etalocib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski